GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care

April 15, 2026

GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine. Through this collaboration, GNQ will deliver its causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms supported by IBM’s consulting expertise and hybrid cloud deployment experience. The collaboration is formalized through a global Joint Initiative Marketing Agreement signed in March 2026.

Healthcare, News

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp.

March 16, 2026

GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “BCA”) pursuant to which IBAC will acquire all of the issued and outstanding shares in the capital of GNQ by way of a statutory plan of arrangement under the Canada Business Corporations Act (the “Transaction”). Following closing of the Transaction, which is expected in the third quarter of 2026, the combined company expects to be publicly listed on Nasdaq. Shares will trade on Nasdaq under the symbol IBAC until the closing of the Transaction.

News, Technology

Seaspring signs strategic cooperation agreement with iSoftStone Digital

October 14, 2025

Seaspring has signed a strategic cooperation agreement with iSoftStone Digital, a sub-brand of iSoftStone, which is a leading Chinese provider that excels in software and digital technology services, computing products, digital energy, and intelligent computing. The two sides will focus on network security and AI to jointly explore the Bahraini and surrounding markets. The collaboration aligns with Bahrain’s national digital economy agenda and fits iSoftStone’s “Full-stack Intelligence+Localization” global strategy, bridging the gap in high-end digital services in the region.

Biotricity, News

Biotricity recognized by Financial Times as one of 2025’s fastest-growing companies in the Americas, growing 256.4% over the period analyzed

April 8, 2025

Biotricity Inc. (“Biotricity”) is proud to announce its inclusion on the Financial Times’ list of The Americas’ Fastest-Growing Companies 2025. This recognition highlights Biotricity’s innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges.

Biotricity, Healthcare, News

Biotricity announces inclusion as a supplier to a prominent medical system that services 21 states

September 26, 2024

Biotricity Inc. (Biotricity) announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. This partnership not only expands Biotricity’s market reach but also underscores its commitment to addressing critical gaps in cardiovascular care across the nation.

Biotricity, News

Biotricity announces continued margin improvement driven by its proprietary AI cloud

July 22, 2024

Biotricity Inc. (Biotricity) today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company’s proprietary AI Cloud platform. The latest version of Biotricity’s AI Cloud has improved the company’s tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters. The next version of the AI Cloud, currently under development, is anticipated to enhance the tech stack by another 20%, contributing to an additional margin improvement of 100 to 200 basis points (1 to 2%). These across-the-board improvements are accelerating Biotricity’s path to breakeven and achieving positive cash flow.

News, Wedge Networks

Wedge Networks Inc. Selected for Government of Canada Innovations Direct Buy Program

March 6, 2024

Wedge Networks Inc. (Wedge) announced today that the Wedge Absolute Real-time Threat Protection Platform has been added to the Government of Canada’s Pathway to Commercialization innovations source list, for direct buy purchase by departments and agencies. Each purchase can be for as much as $8M with no limit on the number of purchases by departments. The source listing will be active for a period of 3 years.

Biotricity, News

Biotricity expands development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats

January 23, 2024

Biotricity Inc. (Biotricity) today announced the expanding development of its future Cardiac AI Cloud platform. The new platform is focused on predictive monitoring to help assist physicians and users to identify issues before they occur, supporting earlier interventions, reducing readmissions, and lowering healthcare costs. Biotricity’s product portfolio is already one of the most comprehensive remote cardiac monitoring portfolios globally. This expansion will further enhance its existing products while providing additional advantages.

News, Wedge Networks

Wedge Networks announces its partner DLS has been awarded the Government of Canada SLSA for 5 years

October 12, 2023

Wedge Networks (Wedge) announced that it’s partner DLS Technology Corporation [DLS] has been awarded a Government of Canada Supply Arrangement under the Software and Licensing Supply Arrangement [SLSA ] for an additional 5 (five) years, through to 2028. This SA underscores DLS’s commitment to providing modern and secure solutions to our government clients. Government of Canada departments, Crown Corporations, and Government Agencies requiring software, licensing, and solutions support can procure through this vehicle with the confidence that they will receive the most favored pricing from trusted DLS and our partners.

Biotricity, News

Biotricity achieves $14 Million Revenue Run Rate in August 2023

August 30, 2023

Biotricity Inc. (Biotricity) today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate. In its Corporate Impact Report published last spring, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.